Stocktobuy
K Technical Analysis 🧙Founded in 1906, Kellogg is a leading global manufacturer and marketer of cereal, cookies, crackers, and other packaged foods. Its offerings are manufactured in 21 countries and marketed in more than 180 countries. Its product mix includes well-known brands such as Special K, Frosted Flakes, Froot Loops, Rice Krispies, Pop-Tarts, Eggo, Kashi, and Morningstar Farms. The firm added the Pringles brand to its mix in 2012. Sales outside its home turf account for around 40% of Kellogg's consolidated sales base.
If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
TOP WSB PLAYS: $GME $AMC $NOK $EXPR $PHUN $NAKDHistory in the making...
$AMC Jan 21st 2022 $40 Calls
$NOK Jan 21st 2022 $17 Calls
Returns +155,000%
$FLYY Very bullish chart in the makingCup forming on on the chart. Easy 6 to 10x play in the making.
Do not miss out on the rocket ride up!
Click a like if you like what you see on the chart
BUY $PFE - NRPicks Ene 17Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. Pfizer mainly sells prescription drugs and vaccines, also spends a leading amount on research and development, close to $8 billion annually.
The company has developed its COVID-19 vaccine, however, it has not reflected its optimism in the stock price. The company has generated the same income quarter by quarter during the year, so we can see a good future for the development of its vaccine and the development of the new strain of the virus.
Fundamentals:
- Value
- P/B 3.1x VS 4.3x Industry
- ROE 22% vs. 17% industry
Technicians:
- Price level below SMA 250-200-150
- Williams R% at -50% levels
- RSI (40) Midlevel
- +1% average upside during the month
As a result of the allergic reactions to the vaccine presented, PFE presented a 15% correction from December 8 to December 31, which stopped at a support of $36.3. From this point on, the stock presented a change in trend, which could continue due to the fact that the stock is below its medium term moving average.
GBS Technical Analysis.Glucose Biosensor Systems (Greater China) Holdings Inc is a United States based company engaged in manufacturing of Saliva Glucose Biosensor (SGB). SGB uses saliva to measure glucose non-invasively. The Saliva Glucose Test consists of the SGB which is a single use disposable saliva biosensor and the software app that interfaces the SGB with its digital information system.
If you understand the idea,🎯 press a thumb up! 👍👍👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
CTK Technical Analysis.If you understand the idea,🎯 press a thumb up! 👍👍👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
Mind Tree - Mid Term SwingHello Everyone,
Today I am sharing my an another idea for mid term swing.
Script Name : Mind Tree
Buy : 774-780
Sl : 720
Target : 835/865/940
Time span : 3-4 Weeks
BHEL- Portfolio Stock - Long Term View Hey everyone,
I consider NSE:BHEL for my Portfolio stock. Will explain everything why I am considering this stock in my Portfolio and what will be My entry Point.
Key Factors
================
1- BHEL has offered partnerships at its 16 manufacturing facilities across the country
2-Company has 14000 acres land parcels at different towns and cities in India. Taking conservative per acre land price at Rs 50 lakhs, the land value is pegged at Rs. 7000 Cr. Further, company has Rs. 5000 Cr cash. So total value of land + cash is Rs. 12000 Cr. Currently company market cap at Rs. 7700 Cr.
3-BHEL has floated an expression of interest form foreign companies to use its idle facilities to set up manufacturing of electrical equipment, solar modules, lithium ion cells, transportation equipment, LCD panels. Can be a big beneficiary of companies looking to diversify manufacturing from China post covid 19.
4-BHEL has mainly fallen due to fall in sales and increase in inventory and trade receivables.
5-BHEL stock has declined 66 per cent in the past one year due to weak power demand, delay in new orders and deteriorating receivables position. The stock offers an attractive risk-reward profile with its current market cap at Rs 8,300 crore against FY19 cash and cash equivalent of Rs 7,503 crore. The stock, with a dividend yield of 8.5 per cent, is currently trading at 0.3 times its book value. Considering its net assets of Rs 35,810 crore as on FY19 and outstanding shares of Rs 348 crore,
Fundamental View
===================
www.dropbox.com
Technical View
====================
BHEL strongest support and demand zone is near about 8-12 rupees. There is lot of confirmation on this price and this is the best price we can get in Upcoming years. We should need to consider a long position from this price.